COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #52 of 260
6/3 Post Exposure Prophylaxis study (treated after exposure to the virus)
Boulware et al., NEJM, June 3 2020, doi:10.1056/NEJMoa2016638 (Peer Reviewed)
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
Source   PDF   Share   Tweet
COVID-19 cases are reduced by [49%, 29%, 16%] respectively when taken within ~[70, 94, 118] hours of exposure (including shipping delay). The treatment delay-response relationship is significant at p=0.002. PEP delayed treatment RCT.
For more detailed analysis, see [1].
6 independent analyses of the data in this study confirm efficacy: [2, 3, 4, 5, 6, 7, 8].
Regarding the use of folic acid, see [9].

Boulware et al., 6/3/2020, Randomized Controlled Trial, USA, North America, peer-reviewed, 24 authors.
risk of COVID-19 case, 17.0% lower, RR 0.83, p = 0.35, treatment 49 of 414 (11.8%), control 58 of 407 (14.3%).
risk of COVID-19 case, 25.1% lower, RR 0.75, p = 0.22, treatment 32 of 414 (7.7%), control 42 of 407 (10.3%), probable COVID-19 cases.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 260 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit